8
Participants
Start Date
May 8, 2014
Primary Completion Date
November 28, 2018
Study Completion Date
November 28, 2018
1 mg/kg GR-MD-02
1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
2 mg/kg GR-MD-02
2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
4 mg/kg GR-MD-02
4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
8 mg/kg GR-MD-02
8 mg/mg GR-MD-02
Ipilimumab
3 mg/kg ipilimumab on Days 1, 22, 43, and 65
Providence Portland Medical Center, Portland
Collaborators (1)
Providence Cancer Center, Earle A. Chiles Research Institute
OTHER
Galectin Therapeutics Inc.
INDUSTRY
Providence Health & Services
OTHER